Search results
Results from the WOW.Com Content Network
On 3 February, World Health Organization Director-General Tedros Adhanom Ghebreyesus said there was no need to "unnecessarily interfere with international travel and trade" in trying to control COVID-19. He said, "We call on all countries to implement decisions that are evidence-based and consistent."
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
In October 2020, the World Health Organization Solidarity trial produced an interim report concluding that its "remdesivir, hydroxychloroquine, lopinavir and interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay."
The World Health Organization has declared that finding where SARS-CoV-2 came from is a priority and that it is "essential for understanding how the pandemic started". [6] In May 2020, the World Health Assembly , which governs the World Health Organization (WHO), passed a motion calling for a "comprehensive, independent and impartial" study ...
On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved. [ 3 ] [ 4 ] By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries.
The World Health Organization (WHO) defines heterologous prime-boost immunization as the "administration of two different vectors or delivery systems expressing the same or overlapping antigenic inserts." [325] A heterologous scheme can sometimes be more immunogenic than some homologous schemes. [326]
[5] [6] In February 2022, the WHO Director General visited China and met the Chinese premier and discussed the need for "stronger collaboration on Covid-19 virus origins, rooted in science and evidence". [7] [8] In July 2023, a review article in The New York Times details information to date about the origins of the Covid-19 virus. [9]
In March, the World Health Organization (WHO) launched the coordinated "Solidarity Trial" in 10 countries on five continents to rapidly assess in thousands of COVID-19 infected people the potential efficacy of existing antiviral and anti-inflammatory agents not yet evaluated specifically for COVID-19 illness.